Denali Therapeutics (DNLI) Equity Ratio (2017 - 2025)
Historic Equity Ratio for Denali Therapeutics (DNLI) over the last 9 years, with Q3 2025 value amounting to 0.88.
- Denali Therapeutics' Equity Ratio fell 324.24% to 0.88 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.88, marking a year-over-year decrease of 324.24%. This contributed to the annual value of 0.89 for FY2024, which is 15.79% up from last year.
- According to the latest figures from Q3 2025, Denali Therapeutics' Equity Ratio is 0.88, which was down 324.24% from 0.88 recorded in Q2 2025.
- Denali Therapeutics' Equity Ratio's 5-year high stood at 0.92 during Q2 2024, with a 5-year trough of 0.66 in Q3 2022.
- Over the past 5 years, Denali Therapeutics' median Equity Ratio value was 0.88 (recorded in 2025), while the average stood at 0.8.
- Per our database at Business Quant, Denali Therapeutics' Equity Ratio plummeted by 1533.38% in 2021 and then skyrocketed by 3682.17% in 2023.
- Quarter analysis of 5 years shows Denali Therapeutics' Equity Ratio stood at 0.69 in 2021, then increased by 4.17% to 0.71 in 2022, then increased by 25.15% to 0.89 in 2023, then rose by 0.16% to 0.89 in 2024, then decreased by 1.95% to 0.88 in 2025.
- Its Equity Ratio was 0.88 in Q3 2025, compared to 0.88 in Q2 2025 and 0.88 in Q1 2025.